XT
DFTX

XTX Topco’s Definium Therapeutics DFTX Stock Holding History

XTX Topco’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,994
Closed -$147K – 4148
2025
Q4 		$147K Buy
+10,994
New +$136K ﹤0.01% 2513
2025
Q3 		– Sell
-32,402
Closed -$210K – 3003
2025
Q2 		$210K Buy
32,402
+2,858
+10% +$18.8K 0.01% 1668
2025
Q1 		$173K Sell
29,544
-6,595
-18% -$47.2K 0.01% 1736
2024
Q4 		$252K Sell
36,139
-23,083
-39% -$159K 0.02% 1358
2024
Q3 		$337K Buy
+59,222
New +$412K 0.02% 1108
2024
Q1 		– Sell
-23,935
Closed -$87.6K – 2142
2023
Q4 		$87.6K Buy
+23,935
New +$72.1K 0.02% 1141
2022
Q4 		– Sell
-20,831
Closed -$73K – 1356
2022
Q3 		$73K Buy
+20,831
New +$200K 0.02% 991
2022
Q1 		– Sell
-3,841
Closed -$79K – 851
2021
Q4 		$79K Buy
+3,841
New +$123K 0.04% 504

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

XTX Topco's DFTX Position: Q1 2026 in Review

XTX Topco sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 10,994 shares — an estimated $147K sold.

XTX Topco first reported a position in DFTX in Q4 2021 and held it in 8 quarters. The position peaked at $337K in Q3 2024. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • XTX Topco reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 10,994 Definium Therapeutics shares in Q1 2026, an estimated $147K.
  • XTX Topco first reported a position in Definium Therapeutics in Q4 2021 and held it in 8 quarters.
  • XTX Topco's Definium Therapeutics position peaked at $337K in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.